Background: The risk of cardiovascular disease (CVD) may differ across ethnic groups, including those who immigrate to Canada, USA and the UK. Accordingly, the absolute and relative benefits of CVD prevention strategies evaluated in randomized clinical trials (RCTs) may differ by the ethnic and immigrant composition of study participants. Methods: We searched MEDLINE, EMBASE and Cochrane databases for RCTs of primary prevention strategies for CVD, published between 1980 and December 2009. We only included RCTs of a CVD primary prevention strategy comprising at least 100 participants aged >19 years, and those published in English. We abstracted data on study and participant characteristics, interventions and outcomes, as well as a description of the immigrants and ethnic composition of the participants. We also recorded whether a study was stratified by immigrant and/or ethnic subgroups in evaluating the efficacy of the study intervention.
Introduction
The age-standardized mortality rate for cardiovascular disease (CVD) declined between 1960 and 2004, yet CVD remains the leading cause of death in North America and the UK. 1 While efforts to prevent CVD have been successful, that process may have shifted the onset of CVD to a later age. 1 In the year 2000, CVD cost Canadians $22.2 billion, and 10% of visits to community physicians were for the management of CVD. CVD also accounted for 17% of all hospitalizations in 2005-06. 2 The changing face of Canada, USA and the UK's ethnic fabric, including a wave of young immigrants from South and East Asia, may alter the aforementioned secular trends in CVD. According to the 2006 Canada Census, immigrants accounted for 20% of the total Canadian population and 28% of the total population of Ontario. 3 In 2007/08, 46% of all Canadian immigrants were living in Ontario. 4 Immigrants may have different genetic, dietary and activity level characteristics than some native-born residents, as well as lower rates of chronic diseases like hypertension. 5 This phenomenon is known as the 'healthy immigrant effect'. 6 We have shown that recent immigrants are at lower risk of stroke and myocardial infarction than long-term residents. 7, 8 At the same time, there may be differences in responses to certain therapies between various ethnic groups. 9 Thus, it may be important to consider the immigrant and ethnic status of participants included in randomized clinical trials (RCTs) of CVD prevention.
We evaluated the proportion of published RCTs of CVD primary prevention that report the immigrant status and ethnicity of study participants and the composition of those immigrant and ethnic subgroups. Within these trials, we also examined whether differences are observed in the efficacy of active treatment between immigrant and ethnic subgroups and other study participants.
Methods

Literature search
We performed a systematic overview by searching MEDLINE, EMBASE and Cochrane databases for studies published between 1980 and December 2009. Two authors (R.H. and S.L.) independently used the following search terms: Cardiovascular disease AND ('Primary Prevention'[Text Word]). All searches were limited to randomized controlled trials, adults aged >19 years, humans and English language studies. The references of the included articles were checked for further relevant RCTs.
Study selection
The same two authors independently read the abstracts of each initial citation and considered it potentially eligible if it met the following criteria:
(i) the study was an RCT; (ii) at least 100 participants in total were recruited; (iii) A primary prevention strategy was evaluated, whether in the form of dietary or lifestyle modification, or a drug or surgical therapy; (iv) CVD was a primary study outcome, whether a myocardial infarction, stroke and/or peripheral arterial disease.
Data abstraction
Using standardized forms, two authors (R.M. and S.L.) independently abstracted from each selected paper information about the study's design, the interventions and outcomes; a description of the immigrant and ethnic subgroups; the primary outcome event rates among all participants, as well as immigrant and ethnic subgroups; and the relative risk reductions for the primary study outcome among all participants, immigrant subgroups and all participants. Details of these abstracted elements are in Tables 1 and 2 .
Data analysis
The proportion of study participants of non-White ethnicity was pooled across studies by a random effects weighting procedure, using Meta-Analyst 0.988 (Lau J. Meta-Analyst 0.988. Boston: MetaAnalyst Statistical Software, 1995). Potential publication bias was assessed by a funnel plot.
Results
Search results and studies included
The combined search strategy for all the three databases yielded 631 potentially relevant studies pertaining to the primary prevention of CVD ( Figure 1 ). Of these, 45 original full-text articles met the selection criteria and were assessed in detail. Only 11 studies (24.4%, 95% CI: 14.3-38.8) included and/or reported on the ethnic status of the participants. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] No study (0.00%, 95% CI: 0.00-0.077) reported the proportion of participants who were immigrants.
Study characteristics
Of the 11 studies that provided some description of the ethnicity of their participants, all were multicenter double-masked RCTs (Table 1) . While one trial was initiated in 1973, 11 the others were completed within the past decade. Nearly all were conducted in the US alone, or in conjunction with other industrialized nations. Two studies exclusively enrolled women. 12, 15 There were 140 764 persons enrolled in all of the trials, at a mean age ranging from 47 11 to 66.3 years. 14 Only four studies (Table 1) . In all 11 RCTs, a medication or nutraceutical was the main active therapy, such as a lipid lowering agent, 10, 11, 13, 16, 17, 20, 21 vitamin/hormonal therapy 10, 14, 15, 19 or an anti-platelet agent 15, 18 (Table 1) . Most trials defined CVD and/or CVD-related death as the primary outcome. The median duration of follow-up was about 5 years.
Ethnicity and related effects
Of the 11 RCTs describing participant ethnicity, 6 classified their participants as White or Black/ African American, with or without Hispanic ancestry. Five studies also included an Asian or Pacific Islander category, and two studies also included First Nations status (Table 2 ). In all 11 trials, the weighted proportion of participants of non-White ethnicity was 10.3% (95% CI: 6.8-15.4). The proportion of Asian or Asian Pacific participants in the four trials that reported on these groups was 2.0% (95% CI: 1.1-3.9). 14, 15, [18] [19] [20] [21] In no study was the therapeutic efficacy of the intervention stratified by ethnicity.
Publication bias
The funnel plot was nearly symmetrical, suggesting no obvious publication bias (Figure 2 ).
Discussion
In this systematic review of 45 published RCTs of primary prevention strategies for CVD, only 11 studies considered participant ethnicity and none reported on immigrant status. No trial considered differences between ethnic groups in the efficacy of the therapeutic interventions studied.
Strengths and limitations
Our literature search and data abstraction were independently conducted by two reviewers. While we only considered studies published in the English language, these were mostly large, practice-changing trials, with a wide international audience. We also acknowledge the possible presence of some publication bias, despite a near-symmetrical funnel plot. Most of the studies reviewed herein were carried out in Western nations, such that the current findings might not be applicable in regions with a large proportion of non-White populations. DBRCT: double-blind randomized clinical trial; LDL-C: serum low-density lipoprotein cholesterol; CRP: serum C-reactive protein; TG: serum triglycerides; TC: serum total cholesterol; MI: myocardial infarction; TIA: transient ischemic attack; CHD: coronary heart disease; NSAID: non-steroidal anti-inflammatory drugs; DM: diabetes mellitus; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL-C: serum high-density lipoprotein cholesterol.
Implications
CVD is a global problem that affects all ethnic groups, yet most of our knowledge about its prevention and treatment comes from studies predominantly conducted among White individuals living in developed countries. Canada (like the UK and USA) is known for its ethnic diversity, with >17% of its citizens being of a visible minority, especially
Chinese, South Asian, Black and First Nations. 22 Moreover, coronary artery disease rates vary among ethnic groups, with the highest burden among South Asians and the lowest among those of Chinese ancestry. 23, 24 Currently, South Asians from India, Pakistan and Bangladesh are the largest and fastest growing ethnic groups in Canada, USA and the UK, comprising 25% of all visible minorities. 22 The dietary practices and levels of activity of recent immigrants may differ from native-born residents, paralleled by lower rates of chronic hypertension 25 -the so-called 'healthy immigrant effect'. 7, 8, 27 Despite this apparent protective effect, South Asians are especially susceptible to premature morbidity and mortality from CVD. [23] [24] [25] [26] Enas et al. 27 found that South Asian migrants to North America, the UK, South Africa and Singapore had a 1.5-4.0 times higher risk of death due to coronary heart disease than indigenously born populations. Risk factors for CVD, including hypertension, diabetes mellitus and dyslipidemia are now emerging as common CVD risk factors within Asia Pacific regions. 28, 29 While CVD is a major global health problem, with the majority of the burden occurring in developing countries, most of our knowledge about its prevention and treatment stems from studies conducted in the industrialized world and predominantly among White populations. 30 Yet, from these RCTs, we also have little information about whether differences exist in the therapeutic efficacy of CVD prevention strategies. Similar information would also be relevant in RCTs evaluating childhood 31 and adult vaccination strategies, such as hepatitis B, 32 as well as in population-based screening trials for malignancy, such as breast cancer, 33 wherein their uptake may differ by ethnicity or immigration history.
When RCTs do assess the ethnicity of their participants, they use rather simple categories, such as White, African-American and Hispanic, which are not reflective of the typical 'fabric' of Canada or the UK. A more detailed classification of ethnicity is recommended, and may be revealing, just as would recency of immigration. Furthermore, it remains to be determined whether there exits a systematic bias in RCT recruitment of individuals from certain ethnic groups, whether some individuals are reluctant to be enrolled in trials and whether this may be partly due to a lesser proficiency in English language, itself a perquisite for the process of informed consent in many RCTs.
Future RCTs should recruit and report on the ethnic and immigrant status of their study groups and the relative efficacy of the studies intervention therein.
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